Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.070-1.200 for the period. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $91.8 million. Simulations Plus also updated its FY25 guidance to $1.07 to $1.20 EPS.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Thursday. KeyCorp assumed coverage on shares of Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. JMP Securities assumed coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They issued a “market perform” rating for the company. Craig Hallum reaffirmed a “buy” rating and issued a $56.00 target price on shares of Simulations Plus in a research report on Wednesday, July 3rd. Finally, BTIG Research dropped their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Simulations Plus Price Performance

SLP stock traded down $0.89 on Friday, reaching $30.07. 182,114 shares of the company traded hands, compared to its average volume of 129,619. The firm has a fifty day simple moving average of $33.20 and a 200-day simple moving average of $40.76. Simulations Plus has a one year low of $29.37 and a one year high of $51.22. The company has a market cap of $601.70 million, a P/E ratio of 64.50 and a beta of 0.69.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The firm had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the previous year, the firm earned $0.18 EPS. Simulations Plus’s quarterly revenue was up 19.9% compared to the same quarter last year. On average, sell-side analysts forecast that Simulations Plus will post 0.54 EPS for the current year.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total transaction of $625,200.00. Following the transaction, the director now owns 3,481,592 shares in the company, valued at approximately $108,834,565.92. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 60,750 shares of company stock worth $2,145,055 over the last quarter. 20.90% of the stock is currently owned by insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.